Onyx offers a virtual immune system platform that securely aggregates multi‑omics data and longitudinal health records from participants in an IRB‑approved environment.
Funding
Funding not disclosed
Founders
Product
Problem
Developing precision medicines for autoimmune diseases is hindered by limited access to comprehensive, longitudinal patient data and integrated multi‑omics profiles, slowing target identification and increasing development risk.
Solution
Onyx provides a virtual immune system platform that aggregates multi‑omics data with patients’ longitudinal health records in a secure, IRB‑approved environment. The platform enables life scientists and AI researchers to analyze richly profiled biospecimens and health histories to discover and validate therapeutic targets more efficiently. Participants contribute health information and samples in exchange for compensation and receive updates on research progress, ensuring ethical data use and participant engagement. By vertically integrating data across molecular and clinical dimensions, Onyx accelerates the pre‑clinical discovery phase and supports the development of more precise autoimmune therapies.
Target Audience
Primary users are pharmaceutical and biotech research teams focused on autoimmune disease drug discovery, as well as academic and AI research groups developing precision medicine approaches.
Features
- Secure, IRB‑overseen collection of health records and biospecimens from study participants
- Integrated multi‑omics profiling (genomics, transcriptomics, proteomics, etc.) linked to longitudinal patient data
- Cloud‑based analytics environment for life scientists and AI researchers to query and model immune system data
- Participant compensation and transparent communication of research updates
- Strict privacy protocols ensuring data is not sold to third parties and is governed by ethical standards